Clementia Pharmaceuticals appoints

Clementia Pharmaceuticals, a privately held clinical stage biotechnology company has appointed three key executives with rare disease and orphan drug expertise: Donna Grogan, M.D., as chief medical officer, Jeff Packman as chief development officer and Eric Grinstead as chief commercial officer. The company is backed by OrbiMed Advisors and BDC Venture Capital.

Practice Fusion raises $70 mln from Kleiner Perkins, OrbiMed, Deerfield

Healthcare records management company Practice Fusion, which is aiming to grow its healthcare platform, has raised a $70 million Series D round of funding led by Kleiner Perkins Caufield & Byers and institutional investors OrbiMed Advisors and Deerfield Management Co. Existing investors, including Artis Ventures, also participated in the round, which brings the total amount raised by the San Francisco-based company to $134 million. As part of the funding, Beth Seidenberg, general partner at Kleiner Perkins, has joined the company board.

ViewRay Raises Fresh $15M for Its Medical Imaging Technology

ViewRay Inc., a Cleveland-based medical device company, has raised $15 million in fresh funding, raising the total amount raised by the company to nearly $100 million. The company’s machinery, which can produce real-time images of cancerous tumors while the tumors are being treated radiation, raised what has been in its biggest round, a $45 million Series C, last year. ViewRay’s investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital.

Cardioxyl Raises Series B Led By OrbiMed

Cardioxyl Pharmaceuticals has secured $28 million in a Series B financing led by OrbiMed Advisors. New investor Osage University Partners joined OrbiMed and returning investors New Enterprise Associates and The Aurora Funds in the financing.

Principia Biopharma Inks $12.5M

Principia Biopharma Inc., a biopharmaceutical company focused on immunology, autoimmune diseases, and oncology, has raised $12.5 million. Investors include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.

RuiYi and arGEN-X Announce License Agreement

arGEN-X BV has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. arGEN-X is backed by OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB.

OrbiMed Advisors In $35 Mln Financing for OmniGuide

OmniGuide has closed a $35 million financing with OrbiMed Advisors. Cambridge, Mass.-based OmniGuide develops advanced energy surgical instruments. PRESS RELEASE OmniGuide Inc., a Cambridge, Massachusetts medical device company specializing in advanced energy surgical products, announced the closing of a $35 million non-dilutive financing with an affiliate of OrbiMed Advisors LLC. The financing structure allows OmniGuide […]

AxioMed Closes Series D Financing

AxioMed Spine Corporation, a spinal orthopedics company has closed its Series D financing, raising $5 million in two tranches from current and new investors. This funding boosts the previously announced $15 million Series D financing. Investors in the business include Siemens Venture Capital, Aisling Capital, Fidelity Biosciences, Kearny Venture Partners and OrbiMed Advisors. PRESS RELEASE […]

Roka Closes Series D

Roka Bioscience has secured $47.5 million in Series D financing. New investor Aisling Capital participated in the financing along with existing investors OrbiMed Advisors, New Enterprise Associates and TPG Biotech. Josh Bilenker, MD, partner at Aisling Capital, will join Roka’s board of directors. Upon completion of theround, the total amount raised since the company’s formation […]

Alexion Pharmaceuticals Buys Enobia Pharma

Alexion Pharmaceuticals Inc. will pay $610 million in cash – and as much as $470 million in future milestone-based payments – to acquire Enobia Pharma Corp. Enobia is a biopharma company developing therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders. Enobia closed a $40 million round earlier this year, and was backed by investors including OrbiMed Advisors, CTI Life Sciences Fund, Desjardins Venture Capital and Lothian Partners.

Acceleron Pharma Inks $30M

Cambridge, Mass.-based Acceleron Pharma Inc. has raised $30 million in financing. The company said that strategic partner Celgene contributed to the round, along with “all other existing investors.” Acceleron has raised capital from Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. The new funds will be used to expand the company’s clinical stage pipeline.

Slideshow: Where the Biotech & Device Investors Are–Q4 Edition

Lately, there’s been a whole lot of bemoaning of this and that to explain why VCs are abandoning the biotech and device space and why strategics are slowing early-stage funding. Lawmakers and regulators have made it too tough to IPO. Lawmakers and regulators have made it too tough to get anything approved at the FDA. […]

arGEN-X Inks $37M Series B

arGEN-X, a biopharmaceutical company developing human monoclonal antibodies, has raised 27.5 million euro ($37 million) in Series B financing. OrbiMed Advisors and Seventure Partners co-led the round, which included participation from existing shareholders Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB. Mike Sheffery of OrbiMed will join the company’s board.

DFINE Adds $25M in Fresh Capital

DFINE Inc., a maker of minimally invasive radiofrequency targeted therapies for the treatment of vertebral pathologies, closed a $25 million. Investors include OrbiMed Advisors, Prospect Venture Partners, Split Rock Partners, BBT Fund/Apothecary Capital, Highland Capital Management and Vanguard Ventures.

Arteaus Therapeutics Inks $18M

Arteaus Therapeutics, a company developing drugs to help prevent migraines, has raised $18 million in new venture capital. Atlas Venture and OrbiMed Advisors provided the financing. Jean-Francois Formela, partner at Atlas Venture, and Thomas Schuetz from OrbiMed, serve on the company’s board. Arteaus is based in Cambridge, Mass.

PE HUB Community

Join the 12519 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget